GSK delivered excellent performance in 2023,
with clear highlights being
the exceptional launch of Arexvy
and continued progress in our pipeline.
We are now planning for at least
12 major launches from 2025,
with new Vaccines and Specialty Medicines
for infectious diseases,
HIV, respiratory and oncology.
As a result of this progress
and momentum,
we expect to deliver another year
of meaningful sales
and earnings growth in 2024,
and we are upgrading our growth outlooks
for 2026 and 2031.
We remain focused on delivering
this potential - and more - to prevent
and change the course of disease
for millions of people.